| Co-Investigator(Kenkyū-buntansha) |
KAMIYA Hiroyuki 北海道大学, 大学院・薬学研究院, 准教授 (10204629)
YAMADA Yuma 北海道大学, 大学院・薬学研究院, 助教 (60451431)
BABA Yoshinobu 名古屋大学, 大学院・工学研究科, 教授 (30183916)
秋田 英万 北海道大学, 大学院・薬学研究院, 助教 (80344472)
小暮 健太朗 京都薬科大学, 薬学部, 教授 (70262540)
中谷 明弘 東京大学, 新領域創成科学研究科, 助教授 (60301149)
|
|---|
| Budget Amount *help |
¥47,840,000 (Direct Cost: ¥36,800,000、Indirect Cost: ¥11,040,000)
Fiscal Year 2009: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2008: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Fiscal Year 2007: ¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
Fiscal Year 2006: ¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
|
|---|
| Research Abstract |
We performed genome-wide screening of type-2 diabetes related genes which can be detectable in blood cells before disease state or after disease occurred. In parallel, we succeeded in developing in vivo gene delivery system for liver..In addition, we constructed an original assay system for nano carriers to evaluate transcytosis of endothelial cells and finally succeeded in finding a selective ligand for transcytosis of nano carriers.
|
